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Introduction
Chk1 is a conserved protein kinase. It was originally identified in
fission yeast [1] and its role was then largely confirmed in verte-
brate cells as a protein kinase required to delay entry of cells with
damaged or unreplicated DNA into mitosis [2, 3]. The involvement
of Chk1 protein kinase in transducing DNA damage signals and its
requirement for both S phase and G2/M checkpoint has been elu-
cidated but few experimental evidence has recently connected
Chk1 to the mitotic spindle checkpoint. This checkpoint ensures
proper chromosome segregation by delaying anaphase until chro-
mosomes are aligned on the spindle thus preventing chromoso-
mal instability, aneuploidy and cancer predisposition [4].
It has been recently proposed that Chk1 is needed in
metaphase for proper chromosome alignment on the equatorial
planes, as shown by a pronounced block in mitosis of Chk1-
depleted HeLa cells [5]. Chk1-deficient cells also fail to sustain 
mitotic arrest after treatment with taxol, which stabilizes micro-
tubules, but do arrest in response to nocodazole (Noc), suggest-
ing that Chk1 helps to sustain anaphase delay when chromosome
biorientation is disrupted [6].
Although the role of Chk1 in DNA damage response has been
largely clarified, its role during normal cell cycle progression
remains controversial. Chk1 -/- mice die at E6.5 days [2] indicating
its fundamental role in early embryonic development. Corroborating
this, a conditional KO of Chk1 induced apoptosis in embryonic mice
stem cells [7] and led to premature mitosis before completion of
DNA replication and cell death by mitotic catastrophe [8]. However,
evidence on the role of Chk1 in somatic cancer and in normal cell
lines and tissues is controversial. The only available vertebrate Chk1
KO somatic cancer cellular system, the DT40 avian lymphoma cell
line Chk1-/-, is viable despite multiple checkpoint and survival
defects [9]. These data are in agreement with what has been report-
ed in various human cancer cell lines where Chk1 depletion by
siRNA did not alter the cell cycle profile or induce apoptosis in the
absence of DNA damage [10, 11]. In contrast, Chk1 is essential for
growth of mammary proliferating epithelial cells and a strong phe-
notype was observed in heterozygosity with general mis-coordination
of the cell cycle due to inappropriate S phase entry, accumulation of
DNA damage during replication and failure to restrain mitotic entry
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[12]. Similar results were recently obtained in U2OS cells in which
Chk1 was depleted either by specific inhibitors or by siRNA, where
aberrant increased intiation of DNA replication was coupled with
generation of DNA strand breaks and H2AX phosphorylation,
although no abnormal cell morphology or investigation of cell sur-
vival at longer time-points after Chk1 inhibition were described [13].
We report here that U2OS cells with Chk1 depleted by siRNA
show an accumulation of polynucleated cells morphologically dis-
tinct from apoptotic cells. In addition, there is accumulation of cells
with a 4N DNA content not associated with an increased number of
mitotic cells and a failure to arrest in mitosis after treatment with
Noc. These data led to the hypothesis that Chk1 function could be
required for activation of the mitotic spindle checkpoint pathway. The
results reported here open up an additional level of complexity on the
role of Chk1 during normal growth, suggesting that depletion of
Chk1 in somatic cancer and normal cell lines may have different con-
sequences depending on the genetic background of the cell lines.
Materials and methods
Cell culture and transfection
Human U2OS osteosarcoma cells were grown in Dulbecco’s modified
Eagle medium supplemented with 10% foetal bovine serum. Cells were
cultured at 37C in 5% CO2. U2OS cells were treated with 75 ng/ml of Noc
(Sigma, St Louis, MO, USA) for 20 hrs, then washed twice in phosphate
buffered saline (PBS) and either starved or recovered in fresh medium and
stored in the incubator for another 7 hrs. Staurosporine treatment was per-
formed for 18 hrs at a concentration of 50 nM.
Small interfering RNA
The Chk1 siRNA duplex target sequence used to deplete Chk1 expression
in U2OS cells is 5 AAGGGATAACCTCAAAATCTC 3. A mismatch in 5 of the
antisense sequence of the double strand RNA was introduced to make 
the down-regulation more efficient, as already described by others [14]. The
siRNA scramble sequence of Chk1 is 5 AAACTATAAGGGTCAACACCT 3.
The siRNA duplexes were synthesized and purchased from Proligo-Sigma
Genosys (Evry Cedex, France). To transfect siRNA duplexes, Lipofectamine
2000 Reagent (Invitrogen, Carlsbad, CA, USA) was used, following the
manufacturer’s instructions.
Western blot analysis
Cells were lysed in ice-cold whole cell extract buffer containing 50 mM Tris
HCl pH 7.4, 250 mM NaCl, 0.1% Nonidet NP40, 5 mM EDTA and NaF
50mM with a protease inhibitor cocktail (Sigma). Lysates were cleared by
centrifuging at 13,000 rpm for 5 min. Around 30 micrograms of total pro-
tein extracts were loaded on 10% SDS-PAGE (6% of SDS-PAGE to detect
BubR1), then transferred to a nitrocellulose membrane.
The polyclonal-sheep antibody against BubR1 was kindly provided by
Doctor Stephen Taylor (Manchester University, UK). The mouse monoclonal
anti-Ran (clone 20) is from BD Transduction Laboratories (Erembodegem,
Belgium). The rabbit phospho-p53 (ser15) antibody is from Cell Signaling
Technology (Danvers, MA, USA). Other primary antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA): anti-Chk1 (G4), p53
(DO-1), cyclin E (HE12), p21 (C-19), Mad2 (FL-205), geminin (FL-209) and
actin (C-11). Densitometric analysis was done with Image J.
Immunofluorescence analysis
To stain with phosphorylated H2AX, U2OS cells were fixed at indicated
time-points with methanol free formaldehyde in PBS 1% for 30 min. on ice,
then in 70% ethanol. Before staining, cells were washed in PBS and treat-
ed with a permeabilization solution (0.5% saponin, 10 mM HEPES, 2.5 mM
CaCl2 and 1.4 M NaCl) for 30 min. at room temperature. Cells were then
stained with monoclonal anti-phospho H2AX (H2AX ser-139, UPSTATE
Upstate Technology, Lake Piacid, NY, USA). Antimouse IgG Alexa Fluor 594
(Molecular Probes Eugene, OR, USA) was used as secondary antibody for
30 min. at room temperature, 1:500 dilution, after three washes in PBS. To
stain with phosphorylated serine 10 Histone 3, LaminB or Aurora B, siRNA
scramble and siRNA Chk1 transfected cells were fixed 72 hrs after transfec-
tion with 4% paraformaldehyde (in PBS solution) for 20 min. at room tem-
perature, washed twice in PBS and stored at 4C. Just before staining cells
were permeabilized for 5 min. with Triton X-100 (0.5% in PBS) then blocked
in Blocking Buffer (2% BSA, 0.2% triton X-100 in PBS) for 1 hr. Monoclonal
anti-histone H3 phosphorylated at serine 10 (6G3, Cell Signaling Technology)
diluted 1:150 was used to stain condensed chromosomes. Polyclonal anti-
lamin B (goat, Santa Cruz Biotechnology) diluted 1:500 was used to stain
the nuclear membrane envelope. The mouse monoclonal Anti-Aurora-B
(AIM1) is from BD Transduction Laboratories.
After each of the above stainings, cells were incubated with DAPI (final
concentration 30 ng/ml in PBS) for 1 min. to stain nuclei, then mounted
with 7 l of Vectashield solution (Vector Laboratories, Burlingame, CA,
USA). To stain with sulforodamine/DAPI solution, after 72 hrs siRNA scram-
ble or siRNA Chk1 transfected cells were incubated for 30 min. in the dark
in a solution of DAPI and sulforodamine dissolved in Na–Tris HCl, pH8.
After further washes with deionized water, the cells on glass coverslips
were mounted in Entellan (Merck, Milan, Italy) and observed in a Zeiss
Axiophot photomicroscope equipped for epifluorescence (Carl Zeiss,
Oberkochen, Germany).
FACS analysis
To detect DNA by FACS, cells were fixed 72 hrs after siRNA transfection;
they were washed twice in ice-cold PBS, fixed in ice-cold 70% ethanol,
washed in PBS, resuspended in 2 ml of a solution containing 25 µg/ml of
propidium iodide in PBS and 25 µl of RNAse 1 mg/ml in water, and stained
overnight at 4C in the dark. Cell cycle analysis was done on at least 10,000
cells for each sample using the FACS Calibur instrument (Becton
Dickinson, HO, USA).
To detect cyclin B1 levels by FACS, cells were fixed in 70% ethanol and
stored at 4C for at least one night. They were then washed in cold PBS,
permeabilized with 0.25% Triton X-100 in PBS for 5 min. on ice. Cells were
then  incubated with 200 l of the anti-cyclin B1 antibody (0.5 g/sample,
clone GNS1 from Pharmingen, San Diego, CA, USA) diluted in rinsing
buffer (1% BSA in PBS), overnight at 4C with gentle agitation. A blank
sample was prepared by incubating cells with 200 l of isotype IgG instead
of cyclin B1. Cells were then washed once before incubation with 200 l of
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Alexa Fluor 488 F(ab’)2 goat antimouse IgG (Molecular Probes) diluted
1:500 in 0.5% (v/v) Tween-20 in PBS for 1 hr, and incubated at room tem-
perature in the dark with gentle agitation. Cells were washed in PBS then
stained for 30 min. at room temperature in the dark with a TP3 solution
containing 0.5 M TO-PRO-3 in PBS and 25 l RNAse 1% in PBS. Cell
cycle analysis was done with a FACS Calibur instrument (Beckton
Dickinson) equipped with a second red iodide laser emitting at 635 nm and
a band pass filter at 661 ± 16 nm for TP3 detection.
The active caspase 3 assay was performed as following described. At 72
and 96 hrs after siRNAs transfection, cells were fixed in 1% paraformalde-
hyde for 1 hr on ice then in 70% ethanol, and stored at 4C. They were
washed once in PBS and permeabilized for 10 min. with 0.004% saponin in
PBS supplemented with 0.5% BSA and 5 mM EDTA. After centrifugation, the
cells were resuspended with 20 µl of anti-active caspase-3 PE antibody
(Becton Dickinson) and incubated for 1 hr in the dark at room temperature.
After washing with PBS, they were analysed with a FACS Calibur instrument
(Beckton Dickinson).
Results
U2OS cells lacking Chk1 show proliferation
defects and alteration of the cell cycle profile
To investigate the role of Chk1 in unstressed conditions, we used
the siRNA strategy to specifically deplete this protein kinase in
U2OS cells. Chk1  protein levels were efficiently down-regulated
from 24 hrs, and the effect persisted up to 144 hrs after transfec-
tion, compared to the scramble siRNA transfected cells (Fig. 1A
and data not shown).
Chk1 depletion in U2OS cells has been recently reported [13]
and we could confirm an increase in H2AX phosphorylation starting
48 hrs after siRNA Chk1 transfection, as compared with the scram-
ble siRNA transfected cells, and persisting up to 72 hrs (Fig. 1B).
We investigated whether Chk1 depletion affected U2OS cell
proliferation. Transfection with the Chk1 siRNA strongly inhibited
cell proliferation, compared to the scramble transfected cells,
starting from 72 hrs and more clearly at 96 hrs (Fig. 1C). Cell cycle
analysis showed an increase in the amount of cells in S and G2/M
phases 72 hrs after transfection (Fig. 1D).
The effects of Chk1 depletion in U2OS cells are different if com-
pared with previous data [10, 11] and with the data showed in Fig. 2,
reporting that Chk1 depletion did not alter the cell proliferation and
the cell cycle profile in various human cancer cell lines (Fig. 2).
Chk1 depletion in U2OS cells leads to 
accumulation of cells with 4N DNA content 
but not of mitotic cells
To better define the nature of the accumulation of U2OS cells lack-
ing Chk1 in S and G2/M phases of the cell cycle, we analysed the
cyclin B1 levels by FACS. Cyclin B1 is specifically expressed in late
S phase and is degraded by E3 ubiquitin ligase activity before
anaphase [4]. Efficient depletion of Chk1 72 hrs after siRNA trans-
fection was confirmed by Western blot analysis (Fig. 3A). The Chk1-
depleted cells at this time showed a consistent accumulation of cells
with 4N DNA content, suggesting they were at the G2/M phase of
the cell cycle (42.7% versus 17.9% in scramble transfected cells).
However, the number of cells positive for cyclin B1 and 4N DNA
content (R2, R3 and R4 boxes, Fig. 3B) was comparable in the
scramble and Chk1 siRNA samples. These findings, together with
the considerable amount of cyclin B1 negative cells in G2/M in the
siRNA Chk1 transfected sample (R1 box, Fig. 3B), suggested that
part of the apparent G2/M population might be tetraploid in G1. This
was confirmed by immunofluorescence (IF) staining using the anti-
body against phospho-H3, a specific mitotic marker, which showed
no accumulation of cells in mitosis and no apparent abnormal mitotic
phenotype in Chk1-depleted U2OS cells (Fig. 3C). There were less
than 3% of phospho-H3 positive cells in the scramble and in the
Chk1-depleted cells thus confirming that the accumulation of cells
with 4N DNA content was not linked to a block in mitosis.
Chk1-depleted U2OS cells show an accumulation
of abnormal micro-polynucleated cells that 
leads to cell death by a predominantly apoptosis
independent mechanism
To investigate whether the lack of proliferation of Chk1-depleted
cells was due to apoptosis, sulforodamine/DAPI staining was
done. We observed both clearly apoptotic (thin arrow, Fig. 4A) and
abnormal micropolynucleated morphologies (thick arrow, 
Fig. 4A) in siRNA Chk1 transfected cells, while the siRNA scram-
ble transfected cells looked morphologically normal (Figs 3C and
4A). Staining with lamin B showed apoptotic cells, which had lost
their nuclear envelope integrity (Fig. 4B, thin arrows), while the
micro-polynucleated cells still had intact lamin B (Fig. 4B, thick
arrow). To quantify the rate of apoptosis, we carried out flow cyto-
metric analysis on cells stained with an antibody that detected
cleaved caspase-3 (Fig. 4C). At 72 and 96 hrs after Chk1 depletion,
there were 6% and 20% of dead cells compared to the scramble
siRNA transfected cells (Fig. 4C). In fact the percentage of viable
cells were, respectively, of 96.10% (scramble) and 90.43% (Chk1)
at 72 hrs and 95.55% (scramble) and 76.38% (Chk1) at 96 hrs
after siRNA transfection (gate R1, Fig. 4C). This suggested that
cell death and/or proliferation defects, inhibiting the growth of
siRNA Chk1 transfected cells, were not uniquely associated with
apoptosis. The micro-polynucleated cells were larger (4A, upper
panel). Interestingly, a subpopulation of the polynucleated cells
were in the last step of cytokinesis with the two daughter cells
containing micronuclei with decondensed DNA but still not com-
pletely separated into two separate cells (Fig. 5A, lower panel). In
addition, these same cells showed an Aurora B positive signal in
the region corresponding to the chromosome bridge (Fig. 5B). The
morphologies observed in siRNA Chk1-treated U2OS cells, shown
in Figs 4 and 5 (panels A and B), might represent cells with a 4N
DNA content exiting from mitosis but not dividing correctly, 
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Fig. 1 Growth survival and cell cycle
profile of U2OS Chk1-depleted cells.
(A) Western blot analysis of Chk1 and
actin in U2OS cells from 72 to 120 hrs
afer siRNAs transfection. (B) pH2AX
immunofluorescence staining in
scramble and Chk1 siRNA-transfected
cells 24, 48 and 72 hrs after transfec-
tion. DAPI staining is also shown. 
(C) Cell growth curve. The data repre-
sent the mean ± S.D. of two independ-
ent experiments. (D) DNA content by
FACS analysis.
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Fig. 2 Effects of Chk1 depletion in various human cancer cell lines. (A) Western blot analysis of Chk1 and Ran in U2OS, A2780, SKOV-3, HCT-116 wt
and HCT-116 p53 -/- 96 hrs after siRNA transfection. (B) Schematic representation of the percentage of cells surviving at 96 hrs after transfection with
siRNA Chk1. Data are expressed as relative percentage of scramble transfected cells and are the mean ± S.D. of two independent experiments. (C) FACS
analysis performed on the different human somatic cancer cell lines at 72 hrs after transfection with either scramble or Chk1 siRNA.
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Fig. 3 Accumulation of U2OS cells with
a 4N DNA content. (A) Western blot
analysis of Chk1 and actin in U2OS
cells 72 hrs after siRNA transfection.
(B) Cell cycle specific expression of
cyclin B1 72 hrs after siRNA transfec-
tion. Cells were double stained with
cyclinB1 and ToPro and FACS analysis
was done at 72 hrs after transfection
with siRNAs. The bi-parametric analy-
sis and the simple DNA content are pre-
sented for each sample. The R1 box
represents the cyclin B1 negative popu-
lation and R2, R3 and R4 boxes show
the different levels of cyclin B1 expres-
sion. (C) Phosphorylated serine 10
Histone 3 and DAPI immunofluores-
cence in U2OS cells 72 hrs after siRNA
transfection. Arrows point to siRNA
Chk1 transfected cells with abnormal
morphology, which are more clearly
represented in the lower part of the fig-
ure. Thick arrow: polymicronucleated
morphology; thin arrow: apoptotic
morphology.
J. Cell. Mol. Med. Vol 13, No 8A, 2009
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leading to accumulation of tetraploid cells in G1. Concurrent with
this, we also observed high levels of p53 and p21 and phosphory-
lation in ser 15 residue of p53 in the siRNA Chk1 transfected cells
72 hrs after transfection (at which time there was clear accumula-
tion of 4N DNA content), suggesting that the G1 tetraploid block
may occur through p53-dependent activation of p21 (Fig. 5C).
Transfection of U2OS cells with a second siRNA directed against a
different Chk1 siRNA target confirmed the results just described
(data not shown) thus suggesting that the effect observed is spe-
cific and uniquely attributable to the lack of Chk1.
Chk1-depleted U2OS cells are unable to arrest in
mitosis following spindle disruption by nocodazole
To investigate whether the abnormal phenotype in Chk1-deplet-
ed U2OS cells was the consequence of a defect in the spindle
checkpoint, U2OS cells transfected with either scramble or siRNA
Chk1 were treated with 75 nM of Noc at 48 hrs after transfection
for 20 hrs, then washed and incubated in Noc-free medium for
another 7 hrs. As shown in Fig. 6A, after 20 hrs of Noc treatment,
most of the siRNA scramble transfected cells had rounded up hav-
ing the typical mitotic morphology, which it was not observed in
the siRNA Chk1 transfected cells. To quantify the cells in mitosis,
cells treated or not with Noc were stained with phospho-H3 and
analysed by IF. As shown in Fig. 6B, less than 2.5% of asynchro-
nous untreated cells transfected with either scramble or Chk1
siRNA appeared phospho-H3 positive. However, 20 hrs of Noc
induced an obvious accumulation of cells in mitosis in siRNA
scramble transfected cells (approximately 40%) whereas the pro-
portion of mitotic cells in Chk1-depleted cells treated with Noc was
much lower (approximately 10%). At 7 hrs after Noc release, the
U2OS siRNA scramble transfected cells had completely re-entered
the cell cycle, exiting from the mitotic block. At this time-point,
Fig. 4 Chk1-depleted cells die by a mechanism predominantly apoptosis independent (A) Sulforodamine-DAPI staining of U2OS cells 72 hrs after
siRNA transfection. The thin yellow arrow indicates a typical apoptotic morphology and the thick one points to a polynucleated cell. (B) Lamin B and
DAPI staining in U2OS cells 72 hrs after transfection. The thin white arrows show the breaking down nuclear envelopes in apoptotic cells and the
thicker one points to the intact nuclear envelope of a micronucleated cell. (C) Bi-parametric forward scatter/caspase-3-PE analysis in U2OS cells eval-
uated at 72 and 96 hrs after transfection. The amount of viable cells is represented by the gate R1. U2OS cells treated with staurosporine (A) were
included in the experiment as positive control (percentage of viable cells in positive control sample: 24.17%).
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fewer than 2% of siRNA Chk1 transfected cells were in mitosis
both with and without Noc treatment. Figure 6C shows the cell
cycle profile of U2OS cells transfected with either scramble or
siRNA Chk1 at different times after Noc treatment: 48 hrs after
transfection, when Noc  treatment started the cell cycle profiles
were very similar in both cell groups. After 20 hrs of incubation in
Noc (0 hr), the cells transfected with the scramble siRNA had a
large proportion with a 4N DNA content indicative of mitotic
arrest. In contrast, after 20 hrs in Noc the cells transfected with
the Chk1 siRNA had a large percentage with less than 4N DNA
content (G1 and S phase) as well as an increase in the population
with a 4N DNA content. By 7 hrs after removal of Noc, the scram-
ble siRNA transfected cells had exited mitotis and had re-entered
the cell cycle, while the siRNA Chk1 transfected cells showed a
persistent peak with a 4N DNA content, similar to the cells that had
received Chk1 siRNA but not Noc. The lack of accumulation of
phospho-H3 positive Chk1 siRNA transfected cells (Fig. 6B),
together with the cell cycle analysis (shown in Fig. 6C), strongly
suggests that the Chk1-depleted cells with the G2/M DNA content
is not related to a Noc-induced mitotic arrest.
To corroborate this finding, we analysed the expression of
cyclin B1, a mitotic cyclin and cyclin E, a G1 cyclin, by Western
blot (Fig. 6D). As expected, cyclin B1 accumulated in scramble
siRNA transfected cells 20 hrs after Noc treatment (Figs. 6D 
Fig. 5 Phenotypical characterization of siRNA Chk1 transfected U2OS cells. (A) DAPI staining of U2OS cells 72 hrs after transfection with siRNA Chk1.
The upper panels (a) give two examples of the massive presence of the micropolynucleated phenotype and the lower panels (b) show micropolynucle-
ated cells appearing at the last stage of cytokinesis with nuclei still attached. (B) Aurora B and DAPI staining of U2OS cells 72 hrs after siRNAs trans-
fection. The white arrows indicate the Aurora B signal in the corresponding chromosome bridge of dividing cells (white circle). (C) Western blot analy-
sis of Chk1, p-ser15 p53, p53, p21 and actin protein levels of U2OS cells 72 hrs after siRNAs transfection.
J. Cell. Mol. Med. Vol 13, No 8A, 2009
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and 7A). No accumulation of cyclin B1 was detected in any other
scramble or Chk1 siRNA transfected samples treated or not with
Noc (Fig. 6D), suggesting again that the higher 4N DNA content
in siRNA Chk1 transfected cells is not related to an accumulation
of mitotic cells. Cyclin E levels, however, appeared higher in all
the siRNA Chk1 transfected samples than the siRNA scramble
transfected cells. To further corroborate the fact that Chk1-deplet-
ed U2OS cells were in G1 phase, geminin levels were investigat-
ed (Fig. 6D, lower part). Geminin fluctuates throughout the cell
cycle with its levels lowest at G1 and consistently elevated in S
and G2. It is degraded by the anaphase-promoting complex (APC)
in mitosis [15]. No accumulation of geminin could be detected in
any siRNA Chk1 transfected samples treated or not with Noc as
compared to siRNA scramble transfected cells. Thus Chk1-
depleted cells, despite their DNA content in the G2 or M phase of
the cell cycle, express high levels of cyclin E, a G1 marker and low
levels of geminin, an S and G2 marker. Once again, p53 and p21
protein levels were increased in Chk1-depleted cells, treated or
not with Noc, suggesting that the G1 block in the tetraploid sta-
tus may occur through the p53 pathway. The high p53 levels after
Noc in the siRNA scramble transfected cells has already been
documented [16]. Our data suggest that Chk1 depletion causes
U2OS to fail to activate the spindle checkpoint induced by unat-
tached kinetochores.
Fig. 6 Effects of nocodazole in siRNA scramble or siRNA Chk1 transfected U2OS cells. (A) DIC microscopy pictures of control and Noc treated (20 hrs
75 nM), scramble and Chk1 siRNA transfected U2OS cells. (B) Mitotic index analysis of cells either treated (+) or not (–) with Noc (released 0 and 
7 hrs after 20 hrs of treatment 75 nM). Cells were fixed with paraformaldehyde and stained with the phospho-H3 antibody and DAPI. The data are the
mean ± S.D. of three independent experiments. The percentage of phospho-H3 positive cells was calculated on at least 300 cells. (C) FACS analysis
showing the DNA profile at the start of Noc treatment (48 hrs after transfection), at the end, and 7 hrs after Noc release. (D) Western blot analysis of
Chk1, cyclinB1, cyclinE, p53, p21, geminin and Ran protein levels at the end and 7 hrs after 20 hrs of Noc treatment. Geminin and its relative Ran were
detected on a different SDS-PAGE (lower panel).
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Possible requirement of Chk1 in U2OS cells 
to activate the mitotic spindle checkpoint 
proteins Mad2 and BubR1
To investigate the molecular mechanisms of the accumulation of
morphologically abnormal G1 tetraploid cells after Chk1 depletion,
and the lack of mitotic arrest in these cells after Noc treatment, we
examined the protein levels of two of the principal components of
the mitotic spindle checkpoint Mad2 and BubR1 [17]. Mad2 and
BubR1 protein levels were lower in the Chk1-depleted cells 72 hrs
after siRNA Chk1 transfection than in siRNA scramble transfect-
ed cells. Chk1 depletion also prevented the accumulation of these
proteins following Noc treatment. BubR1 phosphorylation after
Noc was also absent in the Chk1-depleted cells (Fig. 7A). Figure 7B
shows densitometric analysis of three independent experiments
72 hrs after siRNA scramble or Chk1 transfection. Mad2 and
BubR1 protein levels decreased by 75% and 77% in siRNA Chk1
transfected cells compared to siRNA scramble transfected ones.
Real-time PCR analysis detected no significant decrease in Mad2
and BubR1 mRNAs (data not shown).
Discussion
While the role of Chk1 as a key regulator of the DNA damage and
replication checkpoint has been established, evidence of its role in
unstressed conditions is more controversial. We used the selective
siRNA technique to completely deplete the expression of Chk1 in the
osteosarcoma cell line U2OS. Increased H2AX phosphorylation
Fig. 7 Mitotic spindle checkpoint pro-
tein levels in Chk1-depleted U2OS
cells. (A) Western blot analysis of
Chk1, BubR1, cyclinB1, actin, Mad2
and Ran protein levels in siRNA
scramble and Chk1 transfected cells,
either treated or not with Noc 75 nM
for 20 hrs. Mad2 and Ran protein lev-
els were detected on 10% SDS-PAGE
and the other proteins on 6% SDS-
PAGE. (B) Densitometric analysis of
Mad2 and BubR1 protein levels in
U2OS cells 72 hrs after siRNA Chk1
transfection, compared with the siRNA
scramble transfected cells. Data are
expressed as percentage of siRNA
scramble relative controls, representing
the ratio between Mad2 or BubR1 and
Ran or actin, respectively. Error bars
show the standard deviation from the
mean of three independent experi-
ments.
J. Cell. Mol. Med. Vol 13, No 8A, 2009
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was observed, as previously reported for this cell line [13].
However, unlike previous studies using Chk1 down-regulation,
here we noted that, starting from 72 hrs after Chk1 down-regula-
tion, cells stopped growing and died both by apoptosis and by an
apoptosis independent mechanism, as a consequence of accumu-
lation of abnormal giant, polynucleated tetraploid cells, with evi-
dent G2/M accumulation observed by cell cycle analysis. These
observations contrast with previous data and with data showed in
Fig. 2, reporting that siRNA Chk1 depletion did not alter cell pro-
liferation or the cell cycle profile in other human cancer cell lines
with a different status of p53 under unstressed conditions 
[10, 11], suggesting that the consequences of Chk1 depletion may
differ depending on the experimental system studied.
The results in Chk1-depleted U2OS cells might partly be a
direct consequence of entering mitosis with damaged DNA. Chk1-
depleted U2OS cells have a high incidence of DNA strand breaks
resulting from increased initiation of DNA replication [13]. The
lack of Chk1 would not lead to an efficient S or G2 checkpoint and
efficient repair of DNA damage in these cell cycle phases. Cells
that enter mitosis with extensive DNA damage could encounter
problems with segregation of abnormal chromosomes, which
could lead to defects in mitotic exit and cytokinesis with conse-
quent accumulation of G1 tetraploid cells. These giant microp-
olynucleated cells are prevented from cycling again in a p53- and
p21-dependent manner and subsequently die because of the accu-
mulation of severe DNA damage. The p53- and p21-dependent
activation of the G1 checkpoint after Chk1 depletion might result
in tetraploid cells and may be how Chk1-depleted cells attempt to
repair the damage accumulated in previous cell cycle stages. The
lack of a mitotic block in the presence of abnormal DNA structures
in Chk1-depleted U2OS cells suggests that, as has already been
described in fission and budding yeast [18, 19], the Chk1 protein
kinase has a major role not only in the S and G2 checkpoints but
also in sustaining activation of the spindle checkpoint whenever
cells with damaged DNA enter mitosis. These data thus offer a
new example of conservation of the Chk1 pathway in eukaryotic
systems and new evidence of a role of Chk1 in the mitotic spindle
checkpoint in human cells.
The results described are in contrast with recent observations
in HeLa cells [5]. This might be explained by the different experi-
mental systems and further strengthens the evidence that the lack
of Chk1 may have different consequences depending on the genet-
ic background of the experimental system.
We found that down-regulation of Chk1 in U2OS cells led to
loss of viability, accumulation of tetraploid cells after mitotic fail-
ure and inability to activate the spindle checkpoint and arrest in
mitosis after treatment with the microtubule destabilizing drug
Noc. The mitotic spindle checkpoint acts by inhibiting the APC
required to promote degradation of cyclin B1 and cohesin [4, 20].
The APC is inhibited by preventing its association with Cdc20 [17,
20]. This requires both the checkpoint proteins Mad2 and BubR1,
which inhibit the APC whenever a misaligned or unattached chro-
mosome is detected, thus arresting cells at the metaphase-
anaphase transition [4, 17]. We found that Chk1 down-regulation
in U2OS cells led to lower levels of both Mad2 and BubR1. It has
been previously reported that the lack of Mad2 in human cells led
to a failure of metaphase block after Noc treatment and to an accu-
mulation of micropolynucleated cells with aneuploid DNA content
[21]. Mad2, like Chk1, is essential for mouse embryogenesis as
Mad2 -/- KO mice die at E6.5 as a consequence of chromosome
mis-segregation and apoptosis [22]. This matches with the results
after Chk1 depletion and, along with the finding of Chk1-depend-
ent down-regulation of Mad2 protein, supports the idea that Chk1
and Mad2 may be involved in the same pathway regulating the
accurate progression of mitosis. Experimental evidence supports
this relationship in fission yeast where the Chk1 dependent delay
of metaphase-anaphase transition in mitotic cells with damaged
DNA was Mad2 dependent [18]. It will be important to clearly
define if a direct or indirect interaction between Chk1 and Mad2 is
occurring. Analysis of the Mad2 protein sequence revealed a puta-
tive Chk1 phosphorylatable site at ser195 position [23]. Studies
are now in progress to see whether Chk1 has a part in this Mad2
post-translational modification. The few data available on how
Mad2 phosphorylation functions during the cell cycle are still
incomplete, but ser195 is one putative phosphorylation site [24].
BubR1, together with Mad2, is mainly involved in the mitotic
spindle checkpoint. Both proteins are recruited to unattached kine-
tochores, but only BubR1 appears to be recruited to kinetochores
in the absence of tension [25]. Chk1 is required for phosphoryla-
tion and localization of BubR1 to kinetochores in order to sustain
mitotic delay after activation of the mitotic spindle checkpoint by
taxol, a drug that stabilizes microtubules and increases aberrant
kinetochore microtubule attachments, but not by Noc [6]. Here we
found low BubR1 protein levels in Chk1-depleted U2OS cells, sug-
gesting that its stability too may be directly regulated by Chk1.
Nonetheless, in our experimental system a Chk1-dependent
BubR1 phosphorylation was also observed after Noc treatment.
Furthermore, differently to what has been reported by others [6],
Chk1-depleted U2OS cells were unable to arrest in mitosis after
this treatment, which prevents microtubule polymerization and
spindle formation delaying the metaphase-anaphase transition,
with persistent high levels of cyclin B1. Chk1-depleted U2OS cells
did not accumulate cyclin B1 even in the presence of Noc (Figs 6D
and 7A). Low levels of geminin in Chk1-depleted U2OS cells cor-
roborated the fact that these cells were not accumulated before
mitosis in S and G2 phases. In addition, the high expression of
p21 and cyclin E after Chk1 depletion further suggests that these
cells have by-passed the metaphase block aberrantly and are
blocked in G1 phase, giving rise to a tetraploid population. The
mechanism by which Chk1 inhibition leads to low levels of Mad2
and BubR1 has still to be elucidated. However, our findings clearly
show that Chk1 is required not only in S and G2 checkpoints but
also for activation of the mitotic spindle checkpoint.
These results support an important role for Chk1 in unstressed
conditions and merit more detailed investigation since Chk1 has
been proposed as a potential drug target for anticancer therapies.
As the death of non-tumour proliferating cells limits the 
efficacy of most current chemotherapies, if Chk1 inhibition ‘per se’
1576 © 2009 The Authors
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causes toxicity, this may limit its effectiveness. However, the fact
that U2OS cells are so sensitive to Chk1 depletion suggests that
some tumours at least might be very responsive to Chk1
inhibitors.
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